Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gilberto de Castro

Showing results (131-140 of 156) with videos related to

Pageof 16
Sort By:
Lancet (London, England)|December 30, 2015
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialRoy S Herbst, Paul Baas, Dong-Wan Kim, et al.
The Lancet. Oncology|April 21, 2015
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trialJean-Pascal H Machiels, Robert I Haddad, Jérôme Fayette, et al.
Oral Oncology|April 5, 2022
Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048Danny Rischin, Kevin J Harrington, Richard Greil, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2024
Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV TrialMarcin Dzienis, Juan Cundom, Christian Sebastian Fuentes, et al.
Lung Cancer (Amsterdam, Netherlands)|September 22, 2024
Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension studyMartin Reck, Rafal Dziadziuszko, Shunichi Sugawara, et al.
Trials|December 19, 2021
The influence of a supervised group exercise intervention combined with active lifestyle recommendations on breast cancer survivors' health, physical functioning, and quality of life indices: study protocol for a randomized and controlled trialLuiz Augusto Riani Costa, Raphael F Barreto, Sarah Milani Moraes de Leandrini, et al.
Oral Oncology|May 2, 2021
Direct costs associated with the management of mucositis: A systematic reviewLeticia Rodrigues-Oliveira, Luiz Paulo Kowalski, Marcos Santos, et al.
JCO Global Oncology|May 6, 2021
Impact of the COVID-19 Pandemic on Oncology Clinical Research in Latin America (LACOG 0420)Aline B Lara Gongora, Gustavo Werutsky, Denis L Jardim, et al.
Lancet (London, England)|November 5, 2019
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 studyBarbara Burtness, Kevin J Harrington, Richard Greil, et al.
Jornal Brasileiro De Pneumologia : Publicacao Oficial Da Sociedade Brasileira De Pneumologia E Tisilogia|March 15, 2018
Lung cancer in BrazilLuiz Henrique Araujo, Clarissa Baldotto, Gilberto de Castro, et al.
Pageof 16

Showing results (131-140 of 156) with videos related to

Sort By:
Pageof 16
Lancet (London, England)|December 30, 2015
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialRoy S Herbst, Paul Baas, Dong-Wan Kim, et al.
The Lancet. Oncology|April 21, 2015
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trialJean-Pascal H Machiels, Robert I Haddad, Jérôme Fayette, et al.
Oral Oncology|April 5, 2022
Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048Danny Rischin, Kevin J Harrington, Richard Greil, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2024
Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV TrialMarcin Dzienis, Juan Cundom, Christian Sebastian Fuentes, et al.
Lung Cancer (Amsterdam, Netherlands)|September 22, 2024
Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension studyMartin Reck, Rafal Dziadziuszko, Shunichi Sugawara, et al.
Trials|December 19, 2021
The influence of a supervised group exercise intervention combined with active lifestyle recommendations on breast cancer survivors' health, physical functioning, and quality of life indices: study protocol for a randomized and controlled trialLuiz Augusto Riani Costa, Raphael F Barreto, Sarah Milani Moraes de Leandrini, et al.
Oral Oncology|May 2, 2021
Direct costs associated with the management of mucositis: A systematic reviewLeticia Rodrigues-Oliveira, Luiz Paulo Kowalski, Marcos Santos, et al.
JCO Global Oncology|May 6, 2021
Impact of the COVID-19 Pandemic on Oncology Clinical Research in Latin America (LACOG 0420)Aline B Lara Gongora, Gustavo Werutsky, Denis L Jardim, et al.
Lancet (London, England)|November 5, 2019
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 studyBarbara Burtness, Kevin J Harrington, Richard Greil, et al.
Jornal Brasileiro De Pneumologia : Publicacao Oficial Da Sociedade Brasileira De Pneumologia E Tisilogia|March 15, 2018
Lung cancer in BrazilLuiz Henrique Araujo, Clarissa Baldotto, Gilberto de Castro, et al.
Pageof 16